Company Overview - Moleculin Biotech, Inc. is a late-stage pharmaceutical company focused on developing drug candidates for hard-to-treat cancers and viruses [3] - The company's lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance and cardiotoxicity, currently in development for relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases [3] Recent Developments - The company initiated patient recruitment for its pivotal Phase 3 MIRACLE trial (MB-108) evaluating Annamycin in combination with cytarabine for treating relapsed or refractory AML [4] - Following a successful Phase 1B/2 study (MB-106) and FDA input, the company believes it has de-risked the development pathway for Annamycin's potential approval for AML [4] Additional Pipeline - Moleculin is also developing WP1066, an Immune/Transcription Modulator targeting brain tumors and pancreatic cancers, and a portfolio of antimetabolites including WP1122 for treating pathogenic viruses and certain cancer indications [5] Upcoming Events - The company will report its financial results for Q1 2025 on May 13, 2025, followed by a conference call on May 14, 2025, at 8:30 AM ET [1][2]

Company continues to expand global IP coverage and claims to major markets, now extending to June 2040 HOUSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced the U.S. Patent and Trademark Office (USPTO) has granted two additional U.S. patents with claims covering Annamycin. U.S. patent number 12,257,261 titled, ...

Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025Annamycin is potentially a highly versatile drug capable of working synergistically with numerous mechanistically different FDA approved anticancer first line therapies both in vitro and in vivo HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers an ...

HOUSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced that an abstract regarding the Company's next-generation anthracycline, Annamycin, has been selected for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025, at the McCormick Place Co ...

While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the future earnings of this company is a solid fundamental factor that enhances the prospects of a trend reversal for the stock. Understanding Hammer Chart and the Technique to Trade It A downtrend has been apparent in Moleculin Biotech, Inc. (MBRX) lately. While the stock has lost 8.2% over the past week, it could witness a tre ...

– Initial data readout on track for second half of 2025 HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced the first patient has been dosed in its Phase 3 pivotal trial evaluating Annamycin in combination with Cytarabine (also known as "Ara-C" and for which the combination of Annamycin and Ara-C is referred ...

Investors might want to bet on Moleculin Biotech, Inc. (MBRX) , as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Individu ...

Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2024 Earnings Conference Call March 24, 2025 8:30 AM ET Company Participants Walter Klemp - Chairman and CEO John Paul Waymack - Senior CMO Jonathan Foster - EVP and CFO Conference Call Participants Jonathan Aschoff - Roth Capital Partners Jason McCarthy - Maxim Group Vernon Bernardino - H.C. Wainwright Operator Hello, and welcome to the Moleculin Biotech Fourth Quarter and Full Year 2024 Update Conference Call and Webcast. A question-and-answer session will follow t ...

Moleculin Biotech (MBRX) Q4 2024 Earnings Call March 24, 2025 06:53 PM ET Company Participants Walter Klemp - Founder, Chairman, President & CEOJohn Paul Waymack - Senior CMOJonathan Foster - EVP & CFOJason Mccarthy - Senior Managing DirectorVernon Bernardino - Managing Director Conference Call Participants Jonathan Aschoff - Managing Director, Senior Research Analyst Operator Hello, and welcome to the Molecular Biotech Fourth Quarter and Full Year twenty twenty four Update Conference Call and Webcast. A qu ...

Financial Performance - The company reported a net loss of $21.8 million for the year ended December 31, 2024, compared to a net loss of $29.8 million in 2023[26]. - The weighted average common shares outstanding increased to 3,442,997 in 2024 from 1,975,610 in 2023[26]. Expenses - Research and development (R&D) expenses for the year ended December 31, 2024, were $17.7 million, a decrease of $1.8 million from $19.5 million in 2023[14]. - General and administrative (G&A) expenses decreased to $8.8 million in 2024 from $10.0 million in 2023, primarily due to reduced regulatory and legal services[15]. Cash Position - As of December 31, 2024, the company had cash and cash equivalents of $4.3 million, which, along with $9.3 million from February 2025 financing, is expected to fund operations into Q3 2025[16]. Clinical Trials - The company expects to unblind preliminary data from the first 45 subjects in the MIRACLE trial in the second half of 2025[2]. - The MIRACLE trial will randomize 75 to 90 subjects to receive either high dose cytarabine combined with placebo or Annamycin, with the first unblinding expected in the second half of 2025[5]. - The company completed enrollment in the Phase 2 portion of its U.S. Phase 1B/2 clinical trial for Annamycin as monotherapy for soft tissue sarcoma lung metastases, with a clinical study report expected by the end of April 2025[10]. Regulatory Status - The company received positive FDA guidance for the MIRACLE trial, allowing for a smaller number of subjects in the study[6]. - Annamycin has received Fast Track Status and Orphan Drug Designation from the FDA for the treatment of relapsed or refractory acute myeloid leukemia[11].